Serum BDNF levels before treatment predict SSRI response in depression

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 7, 2011, Pages 1623-1630

  Wolkowitz, Owen M ^a   Wolf, Jessica ^a   Shelly, Wendy ^b   Rosser, Rebecca ^a   Burke, Heather M ^a   Lerner, George K ^a   Reus, Victor I ^a   Nelson, J Craig ^a   Epel, Elissa S ^a   Mellon, Synthia H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antidepressant; Brain derived neurotrophic factor (BDNF); Depression; Neurotrophin; SSRI

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; ESCITALOPRAM; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG RESPONSE; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT DURATION;

ADULT; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; CROSS-OVER STUDIES; DEPRESSION; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 79961126702     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.06.013     Document Type: Article

References (84)

1. Adachi M., Barrot M., Autry A.E., Theobald D., Monteggia L.M. Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy. Biol Psychiatry 2008, 63:642-649.
2. AmericanPsychiatricAssociation Diagnostic and statistical manual of mental disorders DSM-IV-TR fourth edition (text revision) 2000, American Psychiatric Association, Washington, DC.
3. Balu D.T., Hoshaw B.A., Malberg J.E., Rosenzweig-Lipson S., Schechter L.E., Lucki I. Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. Brain Res 2008, 1211:37-43.
4. Berton O., et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006, 311:864-868.
5. Bocchio-Chiavetto L, et al. Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiatry 11: 763-773.
6. Brunoni A.R., Lopes M., Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008, 11:1169-1180.
7. Bus B.A., Molendijk M.L., Penninx B.J., Buitelaar J.K., Kenis G., Prickaerts J., Elzinga B.M., Voshaar R.C. Determinants of serum brain-derived neurotrophic factor. Psychoneuroendocrinology 2011, 36:228-239.
8. Castren E., Rantamaki T. Neurotrophins in depression and antidepressant effects. Novartis Found Symp 2008, 289:43-52. discussion 53-49, 87-93.
9. Castren E., Rantamaki T. Role of brain-derived neurotrophic factor in the aetiology of depression: implications for pharmacological treatment. CNS Drugs 2010, 24:1-7.
10. Castren E., Voikar V., Rantamaki T. Role of neurotrophic factors in depression. Curr Opin Pharmacol 2007, 7:18-21.
11. Deltheil T., Guiard B.P., Cerdan J., David D.J., Tanaka K.F., Reperant C., Guilloux J.P., Coudore F., Hen R., Gardier A.M. Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice. Neuropharmacology 2008, 55:1006-1014.
12. D'Sa C., Duman R.S. Antidepressants and neuroplasticity. Bipolar Disord 2002, 4:183-194.
13. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006, 59:1116-1127.
14. Duman C.H., Schlesinger L., Kodama M., Russell D.S., Duman R.S. A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment. Biol Psychiatry 2007, 61:661-670.
15. Gass P., Hellweg R. Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker for affective disorders?. Int J Neuropsychopharmacol 2010, 13:1-4.
16. Gervasoni N., Aubry J.M., Bondolfi G., Osiek C., Schwald M., Bertschy G., Karege F. Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiology 2005, 51:234-238.
17. Gonul A.S., Akdeniz F., Taneli F., Donat O., Eker C., Vahip S. Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci 2005, 255:381-386. Epub 2005 Apr 2006.
18. Govindarajan A., Rao B.S., Nair D., Trinh M., Mawjee N., Tonegawa S., Chattarji S. Transgenic brain-derived neurotrophic factor expression causes both anxiogenic and antidepressant effects. Proc Natl Acad Sci U S A 2006, 103:13208-13213.
19. Groves J.O. Is it time to reassess the BDNF hypothesis of depression?. Mol Psychiatry 2007, 12:1079-1088.
20. Guo S., Kim W.J., Lok J., Lee S.R., Besancon E., Luo B.H., Stins M.F., Wang X., Dedhar S., Lo E.H. Neuroprotection via matrix-trophic coupling between cerebral endothelial cells and neurons. Proc Natl Acad Sci U S A 2008, 105:7582-7587.
21. Guy W. Clinical Global Impression (CGI) 1976, Department of Health, Education and Welfare, Rockville, MD: U.S. W. Guy (Ed.).
22. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967, 6:278-296.
23. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci 2010, 64:341-357.
24. Hashimoto K., Shimizu E., Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev 2004, 45:104-114.
25. Hellweg R., Ziegenhorn A., Heuser I., Deuschle M. Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment. Pharmacopsychiatry 2008, 41:66-71.
26. Henn F.A., Vollmayr B. Basic pathophysiological mechanisms in depression: what are they and how might they affect the course of the illness?. Pharmacopsychiatry 2004, 37(Suppl 2):S152-S156.
27. Henn F.A., Vollmayr B. Neurogenesis and depression: etiology or epiphenomenon?. Biol Psychiatry 2004, 56:146-150.
28. Hoshaw B.A., Malberg J.E., Lucki I. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res 2005, 1037:204-208.
29. Huang T.L., Lee C.T., Liu Y.L. Serum brain-derived neurotrophic factor levels in patients with major depression: effects of antidepressants. J Psychiatr Res 2008, 42:521-525.
30. Ibarguen-Vargas Y., Surget A., Vourc'h P., Leman S., Andres C.R., Gardier A.M., Belzung C. Deficit in BDNF does not increase vulnerability to stress but dampens antidepressant-like effects in the unpredictable chronic mild stress. Behav Brain Res 2009, 202:245-251.
31. Ikeda Y., Yahata N., Ito I., Nagano M., Toyota T., Yoshikawa T., Okubo Y., Suzuki H. Low serum levels of brain-derived neurotrophic factor and epidermal growth factor in patients with chronic schizophrenia. Schizophr Res 2008, 101:58-66.
32. Joe K.H., Kim Y.K., Kim T.S., Roh S.W., Choi S.W., Kim Y.B., Lee H.J., Kim D.J. Decreased plasma brain-derived neurotrophic factor levels in patients with alcohol dependence. Alcohol Clin Exp Res 2007, 31:1833-1838.
33. Joosten E.A., Houweling D.A. Local acute application of BDNF in the lesioned spinal cord anti-inflammatory and anti-oxidant effects. Neuroreport 2004, 15:1163-1166.
34. Karege F., Perret G., Bondolfi G., Schwald M., Bertschy G., Aubry J.-M. Decreased brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002, 109:143-148.
35. Karege F., Bondolfi G., Gervasoni N., Schwald M., Aubry J.M., Bertschy G. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry. 2005, 57:1068-1072.
36. Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, Knudsen GM, Aznar S. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol 14: 347-353.
37. Kobayashi K., et al. Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: as a biological predictor of response to group cognitive behavioral therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2005, 29:658-663.
38. Kozisek M.E., Middlemas D., Bylund D.B. Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies. Pharmacol Ther 2008, 117:30-51.
39. Krishnan V., Nestler E.J. The molecular neurobiology of depression. Nature 2008, 455:894-902.
40. Krishnan V., et al. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 2007, 131:391-404.
41. Lang U.E., Bajbouj M., Gallinat J., Hellweg R. Brain-derived neurotrophic factor serum concentrations in depressive patients during vagus nerve stimulation and repetitive transcranial magnetic stimulation. Psychopharmacology (Berl) 2006, 187:56-59.
42. Lang U.E., Hellweg R., Seifert F., Schubert F., Gallinat J. Correlation between serum brain-derived neurotrophic factor level and an in vivo marker of cortical integrity. Biol Psychiatry 2007, 62:530-535.
43. Larsen M.H., Hay-Schmidt A., Ronn L.C., Mikkelsen J.D. Temporal expression of brain-derived neurotrophic factor (BDNF) mRNA in the rat hippocampus after treatment with selective and mixed monoaminergic antidepressants. Eur J Pharmacol 2008, 578:114-122.
44. Larsen M.H., Mikkelsen J.D., Hay-Schmidt A., Sandi C. Regulation of brain-derived neurotrophic factor (BDNF) in the chronic unpredictable stress rat model and the effects of chronic antidepressant treatment. J Psychiatr Res 2010, 44:808-816.
45. Lee H.Y., Kim Y.K. Plasma brain-derived neurotrophic factor as a peripheral marker for the action mechanism of antidepressants. Neuropsychobiology 2008, 57:194-199.
46. Lee B.H., Kim H., Park S.H., Kim Y.K. Decreased plasma BDNF level in depressive patients. J Affect Disord 2007, 101:239-244.
47. Li Y., Luikart B.W., Birnbaum S., Chen J., Kwon C.H., Kernie S.G., Bassel-Duby R., Parada L.F. TrkB regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment. Neuron 2008, 59:399-412.
48. Lommatzsch M., Zingler D., Schuhbaeck K., Schloetcke K., Zingler C., Schuff-Werner P., Virchow J.C. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging 2005, 26:115-123.
49. Louie A.K., Lewis T.B., Lannon R.A. Use of low-dose fluoxetine in major depression and panic disorder. J Clin Psychiatry 1993, 54:435-438.
50. Mamounas L.A., Blue M.E., Siuciak J.A., Altar C.A. Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain. J Neurosci 1995, 15:7929-7939.
51. Mamounas L.A., Altar C.A., Blue M.E., Kaplan D.R., Tessarollo L., Lyons W.E. BDNF promotes the regenerative sprouting, but not survival, of injured serotonergic axons in the adult rat brain. J Neurosci 2000, 20:771-782.
52. Martinowich K., Manji H., Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci 2007, 10:1089-1093.
53. Matrisciano F., et al. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res 2009, 43:247-254.
54. Mattson M.P., Maudsley S., Martin B. A neural signaling triumvirate that influences ageing and age-related disease: insulin/IGF-1, BDNF and serotonin. Ageing Res Rev 2004, 3:445-464.
55. Mattson M.P., Maudsley S., Martin B. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci 2004, 27:589-594.
56. Mauri M.C., Laini V., Cerveri G., Scalvini M.E., Volonteri L.S., Regispani F., Malvini L., Manfre S., Boscati L., Panza G. Clinical outcome and tolerability of sertraline in major depression: a study with plasma levels. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:597-601.
57. Mitoma M., Yoshimura R., Sugita A., Umene W., Hori H., Nakano H., Ueda N., Nakamura J. Stress at work alters serum brain-derived neurotrophic factor (BDNF) levels and plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels in healthy volunteers: BDNF and MHPG as possible biological markers of mental stress?. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:679-685.
58. Molendijk M.L., Bus B.A., Spinhoven P., Penninx B.W., Kenis G., Prickaerts J., Voshaar R.O., Elzinga B.M. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 2010, epub ahead of print: 21 September 2010.
59. Monteleone P., Serritella C., Martiadis V., Maj M. Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders. Bipolar Disord 2008, 10:95-100.
60. Oyehaug E., Ostensen E.T., Salvesen B. Determination of the antidepressant agent citalopram and metabolites in plasma by liquid chromatography with fluorescence detection. J Chromatogr 1982, 227:129-135.
61. Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Zhang H, Pavuluri MN. Brain-derived neurotrophic factor gene and protein expression in pediatric and adult depressed subjects. Prog Neuropsychopharmacol Biol Psychiatry 34: 645-651.
62. Piccinni A., et al. Plasma brain-derived neurotrophic factor in treatment-resistant depressed patients receiving electroconvulsive therapy. Eur Neuropsychopharmacol 2009, 19:349-355.
63. Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 2007, 46:281-290.
64. Saarelainen T., et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci 2003, 23:349-357.
65. Sahay A., Hen R. Adult hippocampal neurogenesis in depression. Nat Neurosci 2007, 10:1110-1115.
66. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
67. Sartorius A., Hellweg R., Litzke J., Vogt M., Dormann C., Vollmayr B., Danker-Hopfe H., Gass P. Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. Pharmacopsychiatry 2009, 42:270-276.
68. Schmidt H.D., Duman R.S. Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology 2010, 35:2378-2391.
69. Seifert T., et al. Endurance training enhances BDNF release from the human brain. Am J Physiol Regul Integr Comp Physiol 2010, 298:R372-R377.
70. Sen S., Duman R., Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008, 64:527-532.
71. Serebruany V.L., Suckow R.F., Cooper T.B., O'Connor C.M., Malinin A.I., Krishnan K.R., van Zyl L.T., Lekht V., Glassman A.H. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. Am J Psychiatry 2005, 162:1165-1170.
72. Serra-Millas M., Lopez-Vilchez I., Navarro V., Galan A.M., Escolar G., Penades R., Catalan R., Fananas L., Arias B., Gasto C. Changes in plasma and platelet BDNF levels induced by S-citalopram in major depression. Psychopharmacology 2011, 216:1-8. (Berl).
73. Shimizu E., et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry. 2003, 54:70-75.
74. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002, 22:3251-3261.
75. Siuciak J.A., Lewis D.R., Wiegand S.J., Lindsay R.M. Antidepressant-like effect of brain-derived neurotrophic factor. Pharmacol Biochem Behav 1996, 56:131-137.
76. Surget A., Saxe M., Leman S., Ibarguen-Vargas Y., Chalon S., Griebel G., Hen R., Belzung C. Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. Biol Psychiatry 2008, 64:293-301.
77. Taliaz D., Stall N., Dar D.E., Zangen A. Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis. Mol Psychiatry 2010, 15:80-92.
78. Toups MS, Greer TL, Kurian BT, Grannemann BD, Carmody TJ, Huebinger R, Rethorst C, Trivedi MH. Effects of serum Brain Derived Neurotrophic Factor on exercise augmentation treatment of depression. J Psychiatr Res in press (electronic publication ahead of print).
79. Umene-Nakano W., Yoshimura R., Ueda N., Suzuki A., Ikenouchi-Sugita A., Hori H., Otani K., Nakamura J. Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism. J Psychopharmacol 2009, 24:1764-1771.
80. Wolkowitz O.M., Reus V.I., Mellon S.H. Of sound mind and body: depression, disease, and accelerated aging. Dialogues Clin Neurosci 2011, 13:25-39.
81. Yehuda R. Advances in understanding neuroendocrine alterations in PTSD and their therapeutic implications. Ann N Y Acad Sci 2006, 1071:137-166.
82. Yoshimura R., Mitoma M., Sugita A., Hori H., Okamoto T., Umene W., Ueda N., Nakamura J. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1034-1037.
83. Yoshimura R., Hori H., Ikenouchi-Sugita A., Umene-Nakano W., Ueda N., Nakamura J. Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:722-726.
84. Zoladz J.A., Pilc A., Majerczak J., Grandys M., Zapart-Bukowska J., Duda K. Endurance training increases plasma brain-derived neurotrophic factor concentration in young healthy men. J Physiol Pharmacol 2008, 59(Suppl 7):119-132.